| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
66,383,000 |
| Market
Cap: |
1.33(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$16.53 - $28.72 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 2 |
| Insider 6 Months : 2 |
| Insider 3/6 Months : 4.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
53 |
53 |
53 |
53 |
| Total Buy Value |
$1,013 |
$1,013 |
$1,013 |
$1,013 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
101,351 |
146,351 |
179,848 |
214,693 |
| Total Sell Value |
$2,152,463 |
$3,094,133 |
$3,971,419 |
$5,040,525 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
10 |
11 |
12 |
27 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosa-Bjorkeson Dagmar |
Director |
• • – |
2023-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,007 |
5,007 |
|
- |
|
| Gorman Kevin Charles |
Director |
• • – |
2023-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,007 |
5,007 |
|
- |
|
| Ranieri Richard J |
Director |
• • – |
2023-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,007 |
5,007 |
|
- |
|
| Valente Nancy |
EVP, Chief Development Officer |
• • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
39,296 |
39,296 |
|
- |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• • – |
2023-03-09 |
4 |
S |
$29.88 |
$21,244 |
D/D |
(711) |
36,976 |
|
14% |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2023-03-09 |
4 |
S |
$29.88 |
$77,746 |
D/D |
(2,602) |
249,701 |
|
14% |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• • – |
2023-03-09 |
4 |
S |
$29.88 |
$36,752 |
D/D |
(1,230) |
147,726 |
|
14% |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• • – |
2023-03-09 |
4 |
S |
$29.88 |
$21,244 |
D/D |
(711) |
126,230 |
|
14% |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• • – |
2023-03-09 |
4 |
S |
$29.88 |
$32,688 |
D/D |
(1,094) |
73,364 |
|
14% |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• • – |
2023-03-06 |
4 |
S |
$31.42 |
$127,831 |
D/D |
(4,069) |
74,458 |
|
22% |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2023-03-06 |
4 |
S |
$31.42 |
$183,186 |
D/D |
(5,831) |
252,303 |
|
22% |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• • – |
2023-03-06 |
4 |
S |
$31.42 |
$77,346 |
D/D |
(2,462) |
37,687 |
|
22% |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• • – |
2023-03-06 |
4 |
S |
$31.42 |
$87,148 |
D/D |
(2,774) |
126,941 |
|
22% |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• • – |
2023-03-06 |
4 |
S |
$31.42 |
$131,790 |
D/D |
(4,195) |
148,956 |
|
22% |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• • – |
2023-03-03 |
4 |
S |
$31.54 |
$13,467 |
D/D |
(427) |
40,149 |
|
25% |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2023-03-03 |
4 |
S |
$31.54 |
$89,915 |
D/D |
(2,851) |
258,134 |
|
25% |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• • – |
2023-03-03 |
4 |
S |
$31.54 |
$38,855 |
D/D |
(1,232) |
153,151 |
|
25% |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• • – |
2023-03-03 |
4 |
S |
$31.54 |
$28,984 |
D/D |
(919) |
129,715 |
|
25% |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• • – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,504 |
40,576 |
|
- |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• • – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
15,006 |
78,527 |
|
- |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
52,521 |
260,985 |
|
- |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• • – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
18,758 |
154,383 |
|
- |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• • – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,005 |
130,634 |
|
- |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• • – |
2022-12-19 |
4 |
S |
$27.00 |
$100,910 |
D/D |
(3,737) |
63,521 |
|
-4% |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• – – |
2022-03-09 |
4 |
S |
$28.91 |
$22,810 |
D/D |
(789) |
28,976 |
|
-6% |
|
312 Records found
|
|
Page 2 of 13 |
|
|
0.75 (3.9%) 
